Trius Presents Study Results of Best-in-Class Antibiotics in 11 Posters at ICAAC
Trius Therapeutics Recruits former J&J Clinician as Chief Medical Office
Trius Therapeutics Recruits Merck Executive to Lead Drug Development Efforts
Trius Therapeutics Completes $20 Million Series A Financing and Names CEO
Rx3 Pharmaceuticals Expands Board of Directors
Rx3 Pharmaceuticals Creates New Clinical Advisory Board
Rx3 Pharmaceuticals Awarded Two New NIH Grants Totaling $1.5 Million
People to watch: Jeffrey Stein
Rx3 Pharmaceuticals Expands Board and Management Team
Rx3 Pharmaceuticals Expands Management Team
Rx3 Pharmaceuticals Officially Launched
IDSA - Bad Bugs, No Drugs. As Antibiotic Discovery Stagnates ... A Public Health Crisis Brews
Trius Raises $30 Million in Series B Financing
Trius Initiates U.S. Phase I Trial for its Oxazolidinone
Antibacterial Drug, Torezolid